Integrative MicroRNA Expression Profiling Identifies hsa‐miR‐210‐3p and hsa‐miR‐8075 as Candidate miRNAs Associated With Meningioma Biology

Background Meningiomas are the most common primary intracranial tumors and exhibit variable clinical outcomes. Because current diagnostic tools lack sufficient molecular resolution, novel biomarkers are required to improve disease characterization. MicroRNAs (miRNAs), key post‐transcriptional regulators, have emerged as important players in tumor biology. However, their roles in meningiomas remain underexplored. Methods We conducted an integrative analysis of two publicly available miRNA expression datasets (GSE126563 and GSE88721) to identify miRNAs consistently dysregulated in primary meningiomas. High‐confidence target genes of the most strongly altered miRNAs were predicted using four established databases: miRWalk, miRTarBase, TargetScan, and miRDB. Predicted targets were further assessed at the transcriptomic level using the GSE43290 dataset, and functional enrichment analysis was performed using g:Profiler. Results Thirty miRNAs were consistently dysregulated across both datasets. Among these, hsa‐miR‐210‐3p was the most significantly upregulated miRNA, whereas hsa‐miR‐8075 was the only consistently downregulated miRNA. A total of 29 and 125 target genes were predicted for hsa‐miR‐210‐3p and hsa‐miR‐8075, respectively, and validation revealed inverse expression patterns in GSE43290. Functional enrichment analysis indicated that targets of hsa‐miR‐210‐3p are involved in neuronal ligand transcription and NF‐ κ B signaling, whereas targets of hsa‐miR‐8075 were enriched in synaptic signaling and protein binding pathways. Conclusion Our findings identify hsa‐miR‐210‐3p and hsa‐miR‐8075 as candidate miRNAs with opposing expression patterns and potential regulatory relevance in meningioma. These miRNAs represent promising candidates for further mechanistic and clinical validation in meningioma.